Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Has tamoxifen had its day?

Michael Baum1

  • 1Department of Surgery, University College London, UK. m.baum@ucl.ac.uk

Breast Cancer Research : BCR
|December 11, 2002
PubMed
Summary

Tamoxifen remains crucial for breast cancer adjuvant therapy and chemoprevention. However, aromatase inhibitors like anastrozole are emerging competitors, potentially altering future treatment choices for postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rhizosphere Microbiome Engineering for Climate-Smart Agriculture: From Synthetic Consortia to Precision Decision Support.

Microorganisms·2026
Same author

Tom Stoppard, <i>Arcadia</i>, and chaos theory.

BMJ (Clinical research ed.)·2025
Same author

Whole-genome resequencing of the wild barley diversity collection: a resource for identifying and exploiting genetic variation for cultivated barley improvement.

G3 (Bethesda, Md.)·2025
Same author

On the origin of the late-flowering ppd-H1 allele in barley.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2025
Same author

Breast cancer screening does not improve length or quality of life.

BMJ (Clinical research ed.)·2024
Same author

Fecal Deployment: An Alternative Way of Defensive Host Plant Cardenolide Use by Lilioceris merdigera Larvae.

Journal of chemical ecology·2023

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tamoxifen has historically been a cornerstone in breast cancer management, significantly reducing mortality.
  • Its established role includes adjuvant therapy and chemoprevention for high-risk individuals.

Purpose of the Study:

  • To review the evolving role of tamoxifen in breast cancer treatment.
  • To discuss its future use in light of emerging aromatase inhibitors.

Main Methods:

  • Review of clinical trial data, including ATAC and IBIS trials.
  • Personal perspective on the implications of comparative studies.

Main Results:

  • Tamoxifen has demonstrated a 20-30% decrease in breast cancer mortality.
  • Recent trials suggest aromatase inhibitors may challenge tamoxifen's dominance.

Conclusions:

  • Tamoxifen is likely to remain a primary adjuvant therapy for postmenopausal women with hormone-responsive breast cancer.
  • Aromatase inhibitors, such as anastrozole, represent future competitors, though their long-term impact requires further evaluation.

Related Experiment Videos